News & Trade Shows

News & Trade shows


C-peptide -- January 18, 2005
1/18/2005
 

BIOMERICA LAUNCHES NEW DIABETES DIAGNOSTIC TEST
 
NEWPORT BEACH, Calif., January 18, 2005 – Biomerica, Inc. (OTC BB: BMRA) today announced it is launching a new diabetes diagnostic blood test to measure levels of C-peptide in blood.   C-peptide levels in blood are about 5 to 6 time greater than insulin levels and are more stable.

Measurement of C-peptide levels allows clinicians to differentiate between Type I and Type II diabetes. Of particular interest is its use to indicate the need for progression to insulin therapy in Type II diabetes.    It is also used to determine the cause of low blood sugar (hypoglycemia) and to monitor the recovery after the removal of an insulin-producing tumor of the pancreas.  In addition, a recent study published in the Journal of the National Cancer Institute linked elevated levels of C-peptide with an increased risk of colorectal cancer in men with diabetes. 

“Our new C-peptide test is a substantial product addition to our current diabetic line of tests which help detect the onset of diabetes,” said Zackary Irani, CEO. “The introduction of this product to our already existing customer base should not only result in increased sales, but should enhance BIOMERICA’s presence in the clinical laboratory diabetes market.”


About Biomerica (OTC BB: BMRA)
Biomerica, Inc. (http://www.biomerica.com) is a global medical technology company, based in Newport Beach, CA.  The Company’s diagnostics division manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of significant medical conditions and serious diseases.


The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, increased sales, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.           

<>tp://A